CADL
Candel Therapeutics, Inc.Healthcare · $820M market cap
Verdict
We can't put a fair value on CADL right now. It has lost money in each of its last 3 years, and our valuation needs recent profits to project from.
Business quality
0 of 5 clear the 10% bar. What are the Big Five?
Follow CADL
Track it on your watchlist and see the full analysis. Free.
Create a free accountInsider activity
Since Sep 8, 2026: no open-market purchases, 2 sales worth $3.2M and 2 other filings (stock awards, tax withholding and similar). Why purchases matter
Sales
Tak Paul Peter
Chief Executive Officer · 2026-09-11
Sold
$621K
Tak Paul Peter
Chief Executive Officer · 2026-09-10
Sold
$2.5M
Other filings
About Candel Therapeutics, Inc.
Candel Therapeutics, Inc. is a clinical-stage biopharmaceutical firm based in Needham, Massachusetts, dedicated to developing innovative immunotherapies for cancer patients. Its pipeline features CAN-2409, which is presently in Phase II clinical trials for pancreatic and lung cancers, and has progressed to Phase III for prostate cancer. This therapy also successfully completed Phase Ib/II trials for high-grade…
Biotechnology
Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Oct 3, 2026. How the Payback Price works